New cancer drug NEV801 enters first human trials
Disease control
Completed
This early-stage trial tested a new drug, NEV801, in 78 adults with advanced solid tumors who had no other treatment options. The main goal was to find the safest dose and check for side effects. Researchers also looked for any signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Neovia Oncology Ltd. • Aim: Disease control
Last updated May 15, 2026 00:02 UTC